TABLE 2.

Effects of Eplerenone on Primary and Secondary End Points

History of hypertension
Primary end points	Rate, per 10,000 person- years follow-up (events/follow-up in years)		Rate difference* per 10,000 person-years)	Matched hazard ratio (95% CI)	P value
	Placebo (n=1838)	Eplerenone (n=1838)
Death from any cause	1430 (336/2350)	1058 (260/2457)	−372	0.71 (0.59–0.85)	<0.0001
CV hospitalization or CV death	3029 (603/1991)	2438 (518/2125)	−591	0.82 (0.72–0.94)	0.003
Secondary end points
Death from CV causes	1255 (295/2350)	916 (225/2457)	−339	0.72 (0.59–0.87)	0.001
Sudden death from cardiac causes	511 (120/2350)	374 (92/2457)	−137	0.71 (0.53–0.96)	0.028
Death from AMI	213 (50/2350)	155 (38/2457)	−58	0.72 (0.47–1.13)	0.150
Death from HF	328 (77/2350)	240 (59/2457)	−88	0.70 (0.47–1.04)	0.076
Hospitalization for AMI	723 (161/2227)	588 (138/2348)	−135	0.84 (0.66–1.07)	0.157
Hospitalization for HF	1258 (268/2130)	1116 (251/2250)	−142	0.87 (0.72–1.05)	0.135
No history of hypertension
Primary end points	Placebo (n=1176)	Eplerenone (n=1176)
Death from any cause	1091 (169/1548)	1086 (167/1537)	−5	0.91 (0.72–1.15)	0.435
CV hospitalization or CV death	2188 (298/1362)	2019 (277/1372)	−169	0.91 (0.76–1.10)	0.331
Secondary end points
Death from CV causes	950 (147/1548)	898 (138/1537)	−52	0.89 (0.69–1.15)	0.360
Sudden death from cardiac causes	394 (61/1548)	338 (52/1537)	−137	0.75 (0.49–1.13)	0.170
Death AMI	233 (36/1548)	202 (31/1537)	−31	0.85 (0.51–1.40)	0.523
Death from HF	258 (40/1548)	241 (37/1537)	−17	1.00 (0.60–1.66)	1.000
Hospitalization for AMI	578 (86/1489)	629 (92/1463)	+51	1.05 (0.77–1.45)	0.744
Hospitalization for HF	902 (130/1442)	681 (100/1468)	–221	0.73 (0.55–0.97)	0.028

AMI indicates acute myocardial infarction; CI, confidence interval; CV, cardiovascular; HF, heart failure.